Rare Diseases Report 2021

Mesothelioma trials: Moving toward improved survival


 

References

1. Parikh K et al. Cancer Treat Rev. 2021 Sept 1;99:102250.

2. National Comprehensive Cancer Network (NCCN) Guidelines. Malignant Pleural Mesothelioma. Version 2.2021, published 2021 Feb 16. Accessed 2021 Aug 30. https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf

3. Popat S et al. Ann Oncol. 2020;31(12):1734-45.

4. Fennell D et al. Journal of Thoracic Oncology. 2021 Mar 1;16(3):S62.

5. Baas P et al. [published correction appears in Lancet. 2021 Feb 20;397(10275):670]. Lancet. 2021 Jan 30;397(10272):375-86.

6. Adusumilli PS et al. Cancer Discov. 2021 Jul 15;candisc.0407.2021.

7. Rimner A et al. J Clin Oncol. 2016;34(23):2761-8.

8. Shaikh F et al. J Thorac Oncol. 2017;12(6):993-1000.

9. Trovo M et al. Int J Radiat Oncol Biol Phys. 2021;109(5):1368-76.

Pages

Recommended Reading

SBRT on oligoprogressive lesions: Benefit in lung cancer
MDedge Hematology and Oncology
Success in closing racial survival gap in lung and breast cancer
MDedge Hematology and Oncology
Substantial declines in mortality for most cancers
MDedge Hematology and Oncology
Most oncology trainees encounter discrimination, don’t report it, survey finds
MDedge Hematology and Oncology
EU panel endorses first-of-its-kind lung cancer drug
MDedge Hematology and Oncology
One-quarter of lung cancer patients alive at 5 years
MDedge Hematology and Oncology
Common lung cancer screening tool superior to alternatives
MDedge Hematology and Oncology
Three drugs go head-to-head in advanced lung cancer study
MDedge Hematology and Oncology
Can aspirin prolong survival in patients with NSCLC?
MDedge Hematology and Oncology
Physicians may be overprescribing immunotherapy for unfit cancer patients
MDedge Hematology and Oncology